Alpha Brain Technologies B.V.

Alpha Brain operates at the intersection of neurotechnology, medical devices, and digital health, with a specific focus on predictive rather than purely diagnostic brain monitoring. Its proposed differentiation is the combination of EEG sensing, real-time AI inference, and ultra-low-power processing suitable for wearable or implantable applications. NEVOA-E addresses seizure warning through a wearable patch, while NEVOA-AI represents the broader monitoring and anomaly-detection layer. This gives the company a narrower initial clinical use case than general-purpose brain-computer-interface developers, but potentially a more defined pathway around epilepsy and closed-loop intervention. The company also emphasizes non-invasive hardware and patient-centred design, which may distinguish it from invasive neural-interface approaches. Its small scale, Maastricht base, one documented non-equity assistance round, and limited public operating metrics indicate an early-stage position. Commercial readiness, regulatory progress, clinical validation, and deployment scale remain unclear.

Alpha Brain’s trajectory appears research- and product-development-led rather than commercially scaled. Founded in 2011, the company has a recorded employee range of one to ten people and one documented financing event: non-equity assistance announced on Sep 16, 2021 from YES!Delft and EY Startup Academy. The absence of a disclosed monetary amount, later financing rounds, hiring activity, or revenue indicators makes it difficult to quantify capital efficiency or business expansion. Product development has broadened from a seizure-prediction sensing platform into two identified offerings: NEVOA-E, a wearable patch for continuous monitoring and pre-seizure alerts, and NEVOA-AI, a real-time brain-monitoring system designed to detect anomalies. The website also describes ultra-low-power processing, potential closed-loop intervention, and Project RELIEVE’s multi-generation device program. These elements suggest an effort to move from sensing toward prediction and intervention, which would be a meaningful technical inflection point if validated clinically.